Passage Bio Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Well, good afternoon, everyone, and welcome again to the 5th Annual Guggenheim Genomic Medicines and Rare Disease Conference. My name is Ry Forseth. And here, we have William Chou, part of Passage Bio. He's the Chief Executive Officer, and he's going to give us an overview of the company. Thank you so much for joining us today.
Thanks for having me.
Let's start with a platform review and key updates we can expect for 2023.
Sure. So I'll start out with our GM1 program for GM1 gangliosidosis. So we've treated six -- we've treated eight patients and shared data from the first six. And what we've seen from the first six patients is product has a favorable toxicity profile. We saw no SAEs due to the product. Second is we saw a good biologic response in all the patients treated, and we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |